左心室機能不全の患者でN6-サイクロヘキシル-2'-O-メチラデノシンを使用したA1アデノシン受容体アゴニズムの効果
B D Bertolet1, I S Anand, R J Bryg
1Department of Medicine, University of Florida Health Sciences Center, Gainesville 32610-0277, USA.
Circulation
|September 15, 1996
まとめ
SDZ-WAG 994によるアデノシンA1受容体アゴニズムは,心不全患者の血液動力学を変化させなかった. しかし,PR間隔と心房ナトリウレチンペプチドを増加させ,神経調節における役割を示唆した.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 神経科学は神経科学である.
背景:
- 心不全における神経調節剤としてのアデノシンの役割を調査する.
- 選択的なアデノシンA1受容体アゴニストであるN6-サイクロヘキシル-2'-O-メチラデノシン (SDZ-WAG 994) を利用する.
研究 の 目的:
- 心不全患者のSDZ-WAG 994の血液動力学および電気生理学的効果を評価する.
- 周辺神経系の神経調節剤としてのアデノシンの可能性を調査する.
主な方法:
- 心不全と左心室シストリック機能不全を有する50人の患者は,プラセボまたはSDZ-WAG 994.の異なる用量を受けた.
- 血液動力学および電気生理学的パラメータは24時間監視されました.
- 血液サンプルをノレピネフリンや心房内ナトリウレチンペプチドなどの神経ホルモンマーカーに分析した.
主要な成果:
- 系統的または肺圧,心指数,または心拍数の有意な変化は観察されなかった.
- PR間隔の用量依存的増加は,A1受容体媒介活性を示した.
- 心房内ナトリウレチンペプチドとノレピネフリン濃度の有意な上昇は,最高用量で観察されました.
結論:
- SDZ-WAG 994によるアデノシンA1受容体アゴニズムは,この患者群では静止状態での有意な血液動力学的変化を引き起こさなかった.
- 観察されたPRインターバルと心房内ナトリウレチンペプチドの増加は,A1受容体活性をサポートします.
- ノルエピネフリンの増加は,心不全における周辺神経調節剤としてのアデノシンの役割を示唆する.
関連する概念動画
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...